CL King Initiates Coverage On Integra Lifesciences With Buy Rating, Announces Price Target of $50
CL King Initiates Coverage On Integra Lifesciences With Buy Rating, Announces Price Target of $50
CL King以买入评级启动对Integra Lifesciences的报道，宣布目标股价为50美元
CL King analyst Kristen Stewart initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Buy rating and announces Price Target of $50.
CL King分析师克里斯汀·斯图尔特以买入评级开始报道Integra Lifesciences（纳斯达克股票代码：IART），并宣布目标股价为50美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。